E Pagano1, M De Rosa2, E Rossi2, E Cinconze2, G Marchesini3, R Miccoli4, O Vaccaro5, E Bonora6, G Bruno7. 1. Unit of Cancer Epidemiology, "Città della Salute e della Scienza" Hospital-University of Turin and CPO Piemonte, Turin, Italy. Electronic address: eva.pagano@cpo.it. 2. CINECA Interuniversity Consortium, Health Department, Bologna, Italy. 3. Unit of Metabolic Diseases and Clinical Dietetics, Alma Mater Studiorum University, Bologna, Italy. 4. Department of Endocrinology and Metabolism, Section of Metabolic Diseases and Diabetes, University of Pisa, Italy. 5. Department of Clinical Medicine and Surgery, University of Napoli Federico II, Napoli, Italy. 6. Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Italy. 7. Department of Medical Sciences, University of Turin, Italy.
Abstract
BACKGROUND AND AIMS: In the present population-based study, we aimed to describe the per patient annual healthcare cost of people with diabetes in 2007-2012, to assess the relative burden of diabetes complications and other potential determinants on healthcare costs in the 2012 cohort, and to describe and analyse the determinants of the cost of incident cases diagnosed in 2012. METHODS AND RESULTS: We analysed data from a retrospective cohort of residents in four Italian areas that were served by Local Health Units participating in the ARNO Observatory. Per patient annual healthcare costs (Euros) were estimated as the sum of all the resources supplied during that year (drugs, outpatient care, and hospitalisations). The mean per patient annual healthcare cost increased from €2752 in 2007 to €3191 in 2010, before decreasing to €2791 in 2012. The largest component of these costs was represented by hospitalisations (around €1550, on average; 51.7% of total cost), followed by outpatient care (€422; 14.6%) and drugs (€973; 33.7%). In 2012, the most relevant cost determinants were chronic diabetes complications, with an additional cost due to nephropathy/end stage renal disease (€4683), amputations (€5042), lower extremity revascularization (€4808), and cerebrovascular diseases (€3861). Costs associated with incidence cases were higher than those associated with prevalent. CONCLUSION: The present study provides evidence on the excess of healthcare costs due to diabetes complications in both prevalent and incident cases.
BACKGROUND AND AIMS: In the present population-based study, we aimed to describe the per patient annual healthcare cost of people with diabetes in 2007-2012, to assess the relative burden of diabetes complications and other potential determinants on healthcare costs in the 2012 cohort, and to describe and analyse the determinants of the cost of incident cases diagnosed in 2012. METHODS AND RESULTS: We analysed data from a retrospective cohort of residents in four Italian areas that were served by Local Health Units participating in the ARNO Observatory. Per patient annual healthcare costs (Euros) were estimated as the sum of all the resources supplied during that year (drugs, outpatient care, and hospitalisations). The mean per patient annual healthcare cost increased from €2752 in 2007 to €3191 in 2010, before decreasing to €2791 in 2012. The largest component of these costs was represented by hospitalisations (around €1550, on average; 51.7% of total cost), followed by outpatient care (€422; 14.6%) and drugs (€973; 33.7%). In 2012, the most relevant cost determinants were chronic diabetes complications, with an additional cost due to nephropathy/end stage renal disease (€4683), amputations (€5042), lower extremity revascularization (€4808), and cerebrovascular diseases (€3861). Costs associated with incidence cases were higher than those associated with prevalent. CONCLUSION: The present study provides evidence on the excess of healthcare costs due to diabetes complications in both prevalent and incident cases.
Authors: David C Tabano; Melissa L Anderson; Debra P Ritzwoller; Arne Beck; Nikki Carroll; Paul A Fishman; David C Grossman Journal: J Occup Environ Med Date: 2018-11 Impact factor: 2.162
Authors: Enzo Bonora; Salvatore Cataudella; Giulio Marchesini; Roberto Miccoli; Olga Vaccaro; Gian Paolo Fadini; Nello Martini; Elisa Rossi Journal: BMJ Open Diabetes Res Care Date: 2020-07
Authors: Giorgio Walter Canonica; Giorgio Lorenzo Colombo; Giacomo Matteo Bruno; Sergio Di Matteo; Chiara Martinotti; Francesco Blasi; Caterina Bucca; Nunzio Crimi; Pierluigi Paggiaro; Girolamo Pelaia; Giovanni Passalaqua; Gianenrico Senna; Enrico Heffler Journal: World Allergy Organ J Date: 2019-01-26 Impact factor: 4.084
Authors: Johannes Pöhlmann; Roberta Montagnoli; Giusi Lastoria; Witesh Parekh; Marie Markert; Barnaby Hunt Journal: Clinicoecon Outcomes Res Date: 2019-10-07
Authors: Sarah Elshahat; Paul Cockwell; Alexander P Maxwell; Matthew Griffin; Timothy O'Brien; Ciaran O'Neill Journal: PLoS One Date: 2020-03-24 Impact factor: 3.240